March 2013 FDA Recall Drug by Actavis South Atlantic Llc
D-248-2013 - Failed USP Dissolution Test Requirements

This Class III drug recall was voluntarily initiated by Actavis South Atlantic Llc on March 22, 2013 for the product Drug. The FDA reported the reason for recall as failed usp dissolution test requirements. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-248-2013

Reason for Recall
Failed USP Dissolution Test Requirements: Out-of-specification dissolution results at the 8 hour stability testing point.
Initiated
03-22-2013
Reported
04-24-2013
Quantity
555,672 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Actavis South Atlantic LLC
buPROPion Hydrochloride Extended-Release Tablets (XL) 300 mg, 30-count tablets per bottle, Rx only, Distributed by: Actavis South Atlantic LLC, Sunrise, FL 33325; Packaged by: American Health Packaging, Columbus, OH 43217; NDC 67767-142-30.

Batch or Lot Expiration Information

Lot# : CC1D11A, CC1D12A, CC1D17A, CC1D18A, CD1D05A, CD1D07A, CD1D08A, CD1D14A, CD1D15A, CD1D16A, CE1D08A, Exp 03/13; CE1D03A, CE1D04A, CE1D07A, CE1D06A, CE1D05A, CE1D13A, CE1D14A, CE1D15A, Exp 04/13; CF1D01A, CE1D24A, CF1D02A, Exp 05/13; CH1D08A, CH1D09A, Exp 07/13; CJ1D01A, CH1D11A, CH1D10A, CJ1D09A, CJ1D02A, CJ1D10A Exp 08/13; CL1D05A, CL1D06A, CK1D05B, CK1D06A, Exp 10/13; CL1D08A, CM1D01A, CM1D02A, Exp 11/13